Compare UFG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | INTS |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 24.0M |
| IPO Year | 2025 | 2023 |
| Metric | UFG | INTS |
|---|---|---|
| Price | $1.25 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 10-28-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $195,620,824.00 | N/A |
| Revenue This Year | $41.40 | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | $240.12 | ★ N/A |
| Revenue Growth | ★ 49.71 | N/A |
| 52 Week Low | $0.60 | $0.19 |
| 52 Week High | $11.00 | $2.56 |
| Indicator | UFG | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 44.17 |
| Support Level | $1.15 | $0.37 |
| Resistance Level | $1.44 | $0.42 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 26.83 | 31.21 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.